News
LEGN
45.30
+1.98%
0.88
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 4d ago
Legend Biotech Price Target Maintained With a $87.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Benzinga · 4d ago
Hold Rating on Legend Biotech Amidst Approval of Carvykti and Commercial Manufacturing Challenges
TipRanks · 4d ago
European Approval for Legend Biotech’s Myeloma Treatment
TipRanks · 4d ago
Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
The European Commission has granted approval of CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma. New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse.
Benzinga · 4d ago
CARVYKTI® (CILTACABTAGENE AUTOLEUCEL) APPROVED BY THE EUROPEAN COMMISSION FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Reuters · 4d ago
Weekly Report: what happened at LEGN last week (0415-0419)?
Weekly Report · 5d ago
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
The FDA said on Thursday it will require boxed warnings for all CAR-T cancer therapies. The blood cancer treatments may pose a risk of secondary cancers, the agency said. In November, the FDA announced it was investigating reports of patients developing T-cell malignancies. The agency asked drugmakers to add a boxed warning to the products in January.
Benzinga · 04/19 13:28
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
Seeking Alpha · 04/19 10:13
US FDA mandates label updates on CAR-T cancer therapies
US FDA mandates label updates on CAR-T cancer therapies that use CAR-t technology. The agency said the changes will highlight the serious risk of T-cell blood cancer in patients who use these therapies. In January, the FDA asked drugmakers to add a boxed warning to their therapies.
Reuters · 04/18 22:33
Scotiabank upgrades Legend Biotech to sector outperform
Seeking Alpha · 04/17 20:35
Analyst Ratings For Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. The average price target for Legend Biotech is $84.25. 12 analysts have provided 12-month price targets for the company.
Benzinga · 04/17 14:01
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/17 13:00
Legend Biotech Raised to Sector Outperform From Sector Perform by Scotiabank
Dow Jones · 04/17 12:30
Legend Biotech Price Target Maintained With a $65.00/Share by Scotiabank
Dow Jones · 04/17 12:30
Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
Benzinga · 04/17 12:20
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
TipRanks · 04/17 11:21
LEGEND BIOTECH CORP <LEGN.O>: SCOTIABANK RAISES TO SECTOR OUTPERFORM FROM SECTOR PERFORM
Reuters · 04/17 10:46
More
Webull provides a variety of real-time LEGN stock news. You can receive the latest news about Legend Biotech Corp through multiple platforms. This information may help you make smarter investment decisions.
About LEGN
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.